Renata PLC (DSE:RENATA)
Bangladesh · Delayed Price · Currency is BDT 411.20
-2.50 (-0.60%)
At close: Jan 22, 2026
Renata Revenue
Renata had revenue of 11.31B BDT in the quarter ending September 30, 2025, with 11.22% growth. This brings the company's revenue in the last twelve months to 44.03B, up 14.56% year-over-year. In the fiscal year ending June 30, 2025, Renata had annual revenue of 42.89B with 13.74% growth.
Revenue (ttm)
44.03B
Revenue Growth
+14.56%
P/S Ratio
1.07
Revenue / Employee
5.26M
Employees
8,366
Market Cap
47.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 42.89B | 5.18B | 13.74% |
| Jun 30, 2024 | 37.71B | 4.74B | 14.37% |
| Jun 30, 2023 | 32.97B | 1.90B | 6.12% |
| Jun 30, 2022 | 31.07B | 1.10B | 3.67% |
| Jun 30, 2021 | 29.97B | 5.30B | 21.46% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Square Pharmaceuticals PLC. | 80.13B |
| Beximco Pharmaceuticals PLC. | 46.34B |
| The ACME Laboratories | 37.48B |
| The IBN SINA Pharmaceutical Industry | 12.84B |
| Beacon Pharmaceuticals | 11.58B |
| Navana Pharmaceuticals | 9.52B |
| Unilever Consumer Care | 3.63B |
| Techno Drugs | 3.23B |